Azitra vs Talphera
AZTR and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AZTR and TLPH compare
Talphera is the larger company, worth 13 times as much as Azitra ($47.0M against $3.7M).
Talphera scores higher on the StockData Score (5 against 2 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AZTR | TLPH |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $47.0M |
| Share price | $0.608 | $0.906 |
| Change, 1 year | 50.2% | −29.8% |
| Change, 5 years | – | −93.7% |
| Beta (5Y) | −2.26 | 0.61 |
| Employees | 13 | 12 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× (better) | 4.4× |
| FCF yield | −316% | – |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −65.1% |
| Profitability | ||
| Return on equity | −373% | −98.1% (better) |
| Return on invested capital | −1294% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1220.4× | – |
| Current ratio | 3.11 | 3.19 (better) |
| Altman Z-score | −23.30 (better) | −28.10 |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −70.9% | – |
| Shareholder yield | −70.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | – | 54.4% |
| Held by insiders | 95.8% | 46.8% |
| Insider net buying, 12 months | – | $304K |
| Short interest, % of float | 121% | 4.4% |
Go deeper
- AZTR stock overview
- AZTR income statement
- AZTR valuation and score
- TLPH stock overview
- TLPH income statement
- TLPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.